DURATA THERAPEUTICS ANNOUNCES THE U.S. LAUNCH OF DALVANCE™
July 18, 2014Durata Therapeutics announced that DALVANCE (dalbavancin) for injection is now available for use for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI), following its recent FDA approval on May 23, 2014.
More »
Celator® Pharmaceuticals Provides Update on CPX-351 and Technology Platform at Analyst Day
July 17, 2014Celator® Pharmaceuticals presented updates at their Analyst Day meeting: new applications for their CombiPlex® platform and that their lead candidate CPX-351 will be explored in new patient populations such as New Acute Myeloid Leukemia subsets.
More »
Zogenix Announces Appointment of David Brushwood, J.D., R.Ph., to External Safe Use Board
July 17, 2014Zogenix announced that David Brushwood, J.D., R.Ph., recently-retired Professor Emeritus of Pharmaceutical Outcomes and Policy at the University of Florida, College of Pharmacy, has joined the company’s External Safe Use Board.
More »